Although there are data about the relation between SCFAs production and increased endogen secretion of GLP-1 (to be discussed in the prior section), there is no clear evidence that pharmacotherapy with GLP-1 analogues in humans with T2DM modifies production of SCFAs. The gene discussed is GCG; the disease is type 2 diabetes mellitus.